A Supercharged Charitable Investment Fund To Nurture UK's Biotech Ecosystem
The UK’s largest medical charities, the Wellcome Trust and Cancer Research UK, have backed the formation of a bulked-up £1bn long-term investment fund from the bringing together of Syncona, the CRT Pioneer Fund and BACIT, with the aim of building a self-sustaining UK biotech ecosystem.
You may also be interested in...
Emerging Company Profile: With funding from Cancer Research UK and Syncona – and a wealth of science from its founders – newly launched London-based immuno-oncology company Achilles Therapeutics, believes it has identified cancer's weak spot.
The UK's next-generation engineered T-cell immunotherapy company Autolus Ltd. has raised £40m ($56m) in a Series B financing that includes the first investment by the new UK investment firm, Perceptive Bioscience Investments Ltd., and funding from Woodford Investment Management LLP. The round brings Autolus's total funding to a respectable £70m in less than two years.
Spun out from the University of Oxford, new born NightstarRx is finding its feet in the biopharma field and has closed a $35m series B funding, with which it will boost its inherited retinal disease pipeline.